英格兰SARS-CoV-2感染后糖尿病发病率及COVID-19疫苗接种的影响:一项1600万人的回顾性队列研究
结果显示,COVID-19后2型糖尿病发病率升高,住院患者升高更明显且持续更久,未接种者升高幅度大于接种者。作者认为,重症COVID-19后应检测2型糖尿病,并推广疫苗接种。
要点
- COVID-19后2型糖尿病发病率在最初4周内显著升高,并随时间下降但持续至102周。
- 住院COVID-19患者2型糖尿病发病率升高幅度更大且持续时间更长。
- 未接种疫苗者COVID-19后2型糖尿病发病率升高幅度大于接种者。
核心结论
- COVID-19后2型糖尿病发病率升高,住院患者升高更明显且持续更久,接种疫苗者升高幅度明显较小。
- 作者认为,重症COVID-19后检测2型糖尿病及推广疫苗接种是应对该公共卫生问题的重要工具。
研究设计与样本
- 回顾性队列研究,使用关联电子健康记录,纳入英格兰18至110岁、基线前注册全科医生至少6个月且有性别、地区及区域剥夺数据的存活人群。
- 接种前队列16669943人(2020年1月1日至2021年12月14日),接种队列12279669人,未接种队列3076953人(均为2021年6月1日至12月14日)。
- 排除既往COVID-19诊断者,比较COVID-19诊断后与诊断前或无COVID-19时糖尿病发病率,估计调整风险比(aHR),随访至诊断后102周。
- 结果按COVID-19严重程度(住院或非住院)及糖尿病类型分层。
主要发现
- 接种前队列中,COVID-19后2型糖尿病aHR从第1-4周的4.30(95%CI 4.06-4.55)降至第53-102周的1.24(95%CI 1.14-1.35)。
- 第1-4周,未接种者2型糖尿病aHR为8.76(95%CI 7.49-10.25),接种者为1.66(95%CI 1.50-1.84)。
- 第1-4周,住院COVID-19患者2型糖尿病aHR为28.3(95%CI 26.2-30.5),非住院者为1.95(95%CI 1.78-2.13);住院者第53-102周降至2.04(95%CI 1.72-2.42),非住院者降至1.11(95%CI 1.01-1.22)。
- 约60%的COVID-19后诊断的2型糖尿病患者在COVID-19后4个月仍持续存在。
- 1型糖尿病模式相似,但超额发病率在COVID-19诊断后1年以上未持续。
临床怎么用
- 作者认为,重症COVID-19后检测2型糖尿病及推广疫苗接种是应对该公共卫生问题的重要工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some studies have shown that the incidence of type 2 diabetes increases after a diagnosis of COVID-19, although the evidence is not conclusive. However, the effects of the COVID-19 vaccine on this association, or the effect on other diabetes subtypes, are not clear. We aimed to investigate the association between COVID-19 and incidence of type 2, type 1, gestational and non-specific diabetes, and the effect of COVID- 19 vaccination, up to 52 weeks after diagnosis. METHODS: In this retrospective cohort study, we investigated the diagnoses of incident diabetes following COVID-19 diagnosis in England in a pre-vaccination, vaccinated, and unvaccinated cohort using linked electronic health records. People alive and aged between 18 years and 110 years, registered with a general practitioner for at least 6 months before baseline, and with available data for sex, region, and area deprivation were included. Those with a previous COVID-19 diagnosis were excluded. We estimated adjusted hazard ratios (aHRs) comparing diabetes incidence after COVID-19 diagnosis with diabetes incidence before or in the absence of COVID-19 up to 102 weeks after diagnosis. Results were stratified by COVID-19 severity (categorised as hospitalised or non-hospitalised) and diabetes type. FINDINGS: 16 669 943 people were included in the pre-vaccination cohort (Jan 1, 2020-Dec 14, 2021), 12 279 669 in the vaccinated cohort, and 3 076 953 in the unvaccinated cohort (both June 1-Dec 14, 2021). In the pre-vaccination cohort, aHRs for the incidence of type 2 diabetes after COVID-19 (compared with before or in the absence of diagnosis) declined from 4·30 (95% CI 4·06-4·55) in weeks 1-4 to 1·24 (1·14-1.35) in weeks 53-102. aHRs were higher in unvaccinated people (8·76 [7·49-10·25]) than in vaccinated people (1·66 [1·50-1·84]) in weeks 1-4 and in patients hospitalised with COVID-19 (pre-vaccination cohort 28·3 [26·2-30·5]) in weeks 1-4 declining to 2·04 [1·72-2·42] in weeks 53-102) than in those who were not hospitalised (1·95 [1·78-2·13] in weeks 1-4 declining to 1·11 [1·01-1·22] in weeks 53-102). Type 2 diabetes persisted for 4 months after COVID-19 in around 60% of those diagnosed. Patterns were similar for type 1 diabetes, although excess incidence did not persist beyond 1 year after a COVID-19 diagnosis. INTERPRETATION: Elevated incidence of type 2 diabetes after COVID-19 is greater, and persists for longer, in people who were hospitalised with COVID-19 than in those who were not, and is markedly less apparent in people who have been vaccinated against COVID-19. Testing for type 2 diabetes after severe COVID-19 and the promotion of vaccination are important tools in addressing this public health problem. FUNDING: UK National Institute for Health and Care Research, UK Research and Innovation (UKRI) Medical Research Council, UKRI Engineering and Physical Sciences Research Council, Health Data Research UK, Diabetes UK, British Heart Foundation, and the Stroke Association.
引用
- Taylor K, Eastwood S, Walker V, et al. Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people. Lancet Diabetes Endocrinol. 2024. PMID: 39054034. doi:10.1016/S2213-8587(24)00159-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。